- Joined
- Jun 24, 2012
- Messages
- 4,132
Here are two studies anyone who spends hard earned coin on GH of any kind should be aware of. I know one of these studies has been posted here before, but this first one I had never seen. So I am just passing it along and keeping them current.
1) IM administration superior to Sub-Q. Better CMax and AUC numbers. Not just simply more GH in blood faster, but more concentration over time too.
Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administration
Methods: Healthy trained subjects (10 males, 10 females) received bolus injections of rhGH on three occasions: 0.033 mg/kg s.c., 0.083 mg/kg s.c., and 0.033 mg/kg i.m. Concentrations of 22 and 20 kDa GH, IGF-I, and IGF-binding proteins (IGFBP)-3 were measured repeatedly before and up to 36 h after injection.
Results: Serum GH maximal concentration (Cmax) and area under the time-concentration curve (AUC) were higher after i.m. than s.c. administration of 0.033 mg/kg (Cmax 35.5 and 12.0 μ g/l; AUC 196.2 and 123.8). Cmax and AUC were higher in males than in females (P < 0.01) and pharmacodynamic changes were more pronounced. IGFBP-3 concentrations showed no dose dependency. In response to rhGH administration, 20 kDa GH decreased in females and remained suppressed for 14–18 h (low dose) and 30 h (high dose). In males, 20 kDa GH was undetectable at baseline and throughout the study.
Conclusions: After rhGH administration, pharmacokinetic parameters are mainly influenced by route of administration, whereas pharmacodynamic variables and 20 kDa GH concentrations are determined mainly by gender. These differences need to be considered for therapeutic use and for detection of rhGH doping.
2) AM/PM (2x) administration leads to higher IGF-1 levels versus 1x bolus PM
Metabolic effects of growth hormone ad... [Clin Endocrinol (Oxf). 1994] - PubMed - NCBI
CONCLUSIONS:
Twice-daily GH injections, apart from producing a more physiological serum GH profile, were superior to one injection in increasing serum IGF-I and decreasing IGFBP-1 levels. Both of these changes tend to amplify the effects of the administered GH. Twice-daily injections, however, resulted in lower night-time levels of lipid intermediates.
1) IM administration superior to Sub-Q. Better CMax and AUC numbers. Not just simply more GH in blood faster, but more concentration over time too.
Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administration
Methods: Healthy trained subjects (10 males, 10 females) received bolus injections of rhGH on three occasions: 0.033 mg/kg s.c., 0.083 mg/kg s.c., and 0.033 mg/kg i.m. Concentrations of 22 and 20 kDa GH, IGF-I, and IGF-binding proteins (IGFBP)-3 were measured repeatedly before and up to 36 h after injection.
Results: Serum GH maximal concentration (Cmax) and area under the time-concentration curve (AUC) were higher after i.m. than s.c. administration of 0.033 mg/kg (Cmax 35.5 and 12.0 μ g/l; AUC 196.2 and 123.8). Cmax and AUC were higher in males than in females (P < 0.01) and pharmacodynamic changes were more pronounced. IGFBP-3 concentrations showed no dose dependency. In response to rhGH administration, 20 kDa GH decreased in females and remained suppressed for 14–18 h (low dose) and 30 h (high dose). In males, 20 kDa GH was undetectable at baseline and throughout the study.
Conclusions: After rhGH administration, pharmacokinetic parameters are mainly influenced by route of administration, whereas pharmacodynamic variables and 20 kDa GH concentrations are determined mainly by gender. These differences need to be considered for therapeutic use and for detection of rhGH doping.
2) AM/PM (2x) administration leads to higher IGF-1 levels versus 1x bolus PM
Metabolic effects of growth hormone ad... [Clin Endocrinol (Oxf). 1994] - PubMed - NCBI
CONCLUSIONS:
Twice-daily GH injections, apart from producing a more physiological serum GH profile, were superior to one injection in increasing serum IGF-I and decreasing IGFBP-1 levels. Both of these changes tend to amplify the effects of the administered GH. Twice-daily injections, however, resulted in lower night-time levels of lipid intermediates.